Paper Details

  1. Home
  2. Paper Details

ESPAC-1 trial progress report: the European randomized adjuvant study comparing radiochemotherapy, 6 months chemotherapy and combination therapy versus observation in pancreatic cancer.

Author: BassiC, BegerH, BüchlerM, DervenisC, Fernandez-CruzL, FriessH, KerrD J, LaçaineF, LinkK, NeoptolemosJ P, PederzoliP

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
CongressA conference or meeting where experts in a specific field gather. It provides opportunities for presentations, discussions, and networking, and serves as a place to share expertise and learn about the latest trends in the industry.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This study describes the ESPAC-1 trial, a large study investigating the benefits of adjuvant treatments for resectable pancreatic cancer: radiotherapy, chemotherapy, and a combination of both.
Paper Details　
Original Abstract of the Article :
At the joint International Association of Pancreatology and European Pancreatic Club meeting at King's College, London (July 9-12, 1997), a satellite meeting of the European Study Group for Pancreatic Cancer (ESPAC) met to discuss the progress of the ESPAC-1 trial. This study will address which, if ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1159/000201503

データ提供：米国国立医学図書館（NLM）

ESPAC-1 Trial: Adjuvant Treatment in Pancreatic Cancer

The world of pancreatic cancer research is a vast and unforgiving desert, much like the one I call home. Researchers are constantly searching for effective treatments to combat this deadly disease. This particular study, known as the ESPAC-1 trial, delves into the effectiveness of adjuvant therapies in patients with resectable pancreatic cancer. The researchers set out to determine the benefit of various treatments, including radiotherapy, chemotherapy, and a combination of both, in comparison to a control group receiving no adjuvant therapy. The study, which began in 1994, has already enrolled a significant number of patients, making it the largest of its kind. The researchers are hopeful that the results will provide definitive answers to the long-standing question of whether conventional adjuvant treatments are truly beneficial for patients with pancreatic cancer.

A Pivotal Study for Pancreatic Cancer Treatment

The ESPAC-1 trial, with its impressive sample size, holds great promise for advancing our understanding of adjuvant therapy in pancreatic cancer. The study's findings could potentially lead to improved treatment strategies and offer hope to countless patients facing this challenging disease.

Impact on Patients and Future Research

This research has the potential to reshape the landscape of pancreatic cancer treatment, providing valuable insights for both clinicians and patients. The results could lead to more targeted and effective adjuvant therapy options, ultimately improving patient outcomes. Furthermore, this study serves as a foundation for future research, paving the way for even more innovative and effective treatments in the years to come.

Dr. Camel's Conclusion

The ESPAC-1 trial is like a beacon of hope in the vast desert of pancreatic cancer research. It holds the potential to illuminate the path towards more effective treatments, improving the lives of countless patients facing this challenging disease.

Date :
  1. Date Completed 1998-03-11
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

9438604

DOI: Digital Object Identifier

10.1159/000201503

Related Literature

Article Analysis
・Effective treatment of pancreatic cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.